ArriVent BioPharma, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving ArriVent BioPharma, Inc. now
Current reporting with the operating signal separated from the noise.
Guggenheim Remains a Buy on ArriVent BioPharma, Inc. (AVBP)
The development tests whether ArriVent BioPharma, Inc. can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.ArriVent BioPharma, Inc. (AVBP) Receives a Buy from Oppenheimer
The story matters when it changes ArriVent BioPharma, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest AVBP filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
ArriVent BioPharma, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →